NASDAQ:STOK Stoke Therapeutics (STOK) Stock Forecast, Price & News $13.08 -0.12 (-0.91%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$12.86▼$13.4050-Day Range$7.93▼$13.2052-Week Range$6.88▼$22.87Volume137,346 shsAverage Volume175,781 shsMarket Capitalization$578.01 millionP/E RatioN/ADividend YieldN/APrice Target$25.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Stoke Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside95.0% Upside$25.50 Price TargetShort InterestBearish17.02% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.16Based on 5 Articles This WeekInsider TradingSelling Shares$667,048 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.53) to ($3.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector550th out of 981 stocksPharmaceutical Preparations Industry261st out of 477 stocks 3.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.50, Stoke Therapeutics has a forecasted upside of 95.0% from its current price of $13.08.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.02% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 3.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 2.9 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Stoke Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $667,048.00 in company stock.Percentage Held by Insiders12.70% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.53) to ($3.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -5.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Stoke Therapeutics (NASDAQ:STOK) StockStoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.Read More Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Stock News HeadlinesJune 7, 2023 | americanbankingnews.comBarry Ticho Sells 15,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) StockMay 26, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Stoke Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:STOK)June 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 25, 2023 | americanbankingnews.comCantor Fitzgerald Raises Stoke Therapeutics (NASDAQ:STOK) Price Target to $25.00May 25, 2023 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Analyst UpgradeMay 24, 2023 | msn.comCantor Fitzgerald Maintains Stoke Therapeutics (STOK) Overweight RecommendationMay 23, 2023 | markets.businessinsider.com12 Analysts Have This to Say About Stoke TherapeuticsMay 23, 2023 | benzinga.comWhere Stoke Therapeutics Stands With AnalystsJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 12, 2023 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Moderate Buy" by AnalystsMay 9, 2023 | finance.yahoo.comHow Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91%May 9, 2023 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For Stoke Therapeutics, Inc. (NASDAQ:STOK)May 9, 2023 | americanbankingnews.comWedbush Comments on Stoke Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:STOK)May 6, 2023 | msn.comCredit Suisse Reiterates Stoke Therapeutics (STOK) Outperform RecommendationMay 6, 2023 | finance.yahoo.comEarnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting Their EstimatesMay 6, 2023 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 24,967 SharesMay 6, 2023 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells $250,427.58 in StockMay 6, 2023 | msn.comNeedham Reiterates Stoke Therapeutics (STOK) Buy RecommendationMay 6, 2023 | msn.comHC Wainwright & Co. Reiterates Stoke Therapeutics (STOK) Buy RecommendationMay 5, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Stoke Therapeutics (STOK)May 5, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Stoke Therapeutics (STOK)May 4, 2023 | msn.comStoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesMay 4, 2023 | msn.comStoke Therapeutics: Q1 Earnings InsightsMay 4, 2023 | benzinga.comStoke Therapeutics Chief Medical Officer Trades Company's StockMay 3, 2023 | finance.yahoo.comStoke Therapeutics to Present at the BofA Securities Health Care ConferenceMay 2, 2023 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?May 2, 2023 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Upgraded by Bank of America to "Neutral"See More Headlines STOK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Company Calendar Last Earnings5/04/2023Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.50 High Stock Price Forecast$35.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+95.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,070,000.00 Net Margins-679.83% Pretax Margin-679.83% Return on Equity-47.86% Return on Assets-35.44% Debt Debt-to-Equity RatioN/A Current Ratio8.57 Quick Ratio8.57 Sales & Book Value Annual Sales$12.40 million Price / Sales46.61 Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book2.79Miscellaneous Outstanding Shares44,190,000Free Float38,577,000Market Cap$578.01 million OptionableNot Optionable Beta0.40 Key ExecutivesEdward M. KayeChief Executive Officer & DirectorHuw M. NashChief Operating & Business OfficerStephen J. TulipanoChief Financial OfficerBarry S. TichoChief Medical OfficerIsabel AznarezGroup Vice President-Discovery ResearchKey CompetitorsOcular TherapeutixNASDAQ:OCUL2seventy bioNASDAQ:TSVTBioXcel TherapeuticsNASDAQ:BTAIZymeworksNYSE:ZYMEGH ResearchNASDAQ:GHRSView All CompetitorsInsiders & InstitutionsBarry TichoSold 15,000 sharesTotal: $166,950.00 ($11.13/share)JPMorgan Chase & Co.Bought 90,608 shares on 5/18/2023Ownership: 0.259%Geode Capital Management LLCBought 12,456 shares on 5/16/2023Ownership: 1.101%State Street CorpBought 7,879 shares on 5/16/2023Ownership: 0.954%Jane Street Group LLCBought 12,856 shares on 5/16/2023Ownership: 0.076%View All Insider TransactionsView All Institutional Transactions STOK Stock - Frequently Asked Questions Should I buy or sell Stoke Therapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STOK shares. View STOK analyst ratings or view top-rated stocks. What is Stoke Therapeutics' stock price forecast for 2023? 8 brokerages have issued 1 year price targets for Stoke Therapeutics' shares. Their STOK share price forecasts range from $12.00 to $35.00. On average, they anticipate the company's stock price to reach $25.50 in the next year. This suggests a possible upside of 95.0% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts. How have STOK shares performed in 2023? Stoke Therapeutics' stock was trading at $9.23 at the beginning of 2023. Since then, STOK shares have increased by 41.7% and is now trading at $13.08. View the best growth stocks for 2023 here. When is Stoke Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our STOK earnings forecast. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its earnings results on Thursday, May, 4th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.17. The company earned $5.15 million during the quarter, compared to the consensus estimate of $3.57 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 47.86% and a negative net margin of 679.83%. What ETFs hold Stoke Therapeutics' stock? ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Direxion mRNA ETF (MSGR), Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree BioRevolution Fund (WDNA), Global X Genomics & Biotechnology ETF (GNOM), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC) and What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA). When did Stoke Therapeutics IPO? (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Stoke Therapeutics' stock symbol? Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK." Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RTW Investments LP (9.94%), Cowen AND Company LLC (7.42%), Baker BROS. Advisors LP (4.79%), FMR LLC (4.45%), BlackRock Inc. (4.18%) and Deutsche Bank AG (1.62%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Stoke Therapeutics' stock price today? One share of STOK stock can currently be purchased for approximately $13.08. How much money does Stoke Therapeutics make? Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $578.01 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. How many employees does Stoke Therapeutics have? The company employs 102 workers across the globe. How can I contact Stoke Therapeutics? Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com. This page (NASDAQ:STOK) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.